The $8 Billion Bet That Nuclear Medicine Is the Future of Cancer Care
Curium just agreed to buy Lantheus Holdings for up to $8 billion, making it the largest pure-play radiopharmaceutical deal in history. The megadeal signals that nuclear medicine's transformation of cancer care is no longer a niche bet; it's a full-blown arms race.
A Company Worth $7 Billion Just Swallowed One Worth $8 Billion
Imagine a mid-sized restaurant chain buying an equally large competitor. That's basically what just happened in nuclear medicine. Curium, a privately held radiopharmaceutical company valued at roughly $7 billion, agreed to acquire Lantheus Holdings for up to $8 billion. It's the largest pure-play radiopharmaceutical acquisition ever, and it says something loud about where cancer treatment is headed.
The deal structure: Lantheus shareholders get $102.50 per share in cash at closing, plus contingent value rights (CVRs) worth up to $12.00 per share if certain commercial milestones are hit through 2030. That brings the maximum total to $114.50 per share. For context, the offer represents a 21% premium over Lantheus' unaffected stock price before deal rumors started swirling, and a 38% premium to its 60-day volume-weighted average price.
Closing is expected in the first half of 2027, pending shareholder and regulatory approvals. After that, Lantheus goes private.
Why Curium Wants Lantheus (and Why It Makes Sense)
Curium isn't some scrappy startup swinging above its weight class. The company was formed in 2017 by merging IBA Molecular and Mallinckrodt Nuclear Medicine, and it's backed by private equity firm CapVest Partners. It operates one of the world's largest vertically integrated nuclear medicine manufacturing networks: multiple production plants, over 45 radiopharmacies, a molybdenum-99 processing facility, and operations spanning more than 70 countries.
But Curium's strength is mostly in Europe and global manufacturing. Its U.S. commercial footprint, particularly in diagnostic imaging, has room to grow. That's where Lantheus fills the gap perfectly.
Lantheus is a U.S. diagnostic powerhouse. Its flagship product, PYLARIFY, is a PET imaging agent used to detect prostate cancer. The company pulled in roughly from PYLARIFY alone in 2025. It also has NEURACEQ for Alzheimer's imaging, a pipeline of new diagnostic agents, and an emerging theranostics strategy (the pairing of diagnostic imaging with targeted radioactive therapies).
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
$989 million
Think of it like a lock-and-key situation. Curium brings the global manufacturing muscle and therapeutic pipeline. Lantheus brings the U.S. commercial engine and diagnostic expertise. Together, they cover the full nuclear medicine value chain, from isotope production to patient scans to targeted radiotherapy.
The PYLARIFY Problem (and Why Curium Doesn't Care)
If this deal sounds too clean, there's a wrinkle. PYLARIFY, Lantheus' crown jewel, is shrinking.
After years of explosive growth (revenue jumped nearly 30% year-over-year in Q2 2024), the product hit a wall. Full-year 2025 PYLARIFY revenue fell 6.5% compared to 2024, dropping from $1.06 billion to $989 million. The declines accelerated through the year, with Q4 2025 sales down nearly 10%.
Lantheus' overall guidance for 2026 reflects this softness: $1.4 to $1.45 billion in total revenue, down from $1.49 to $1.51 billion in 2025.
So why would Curium pay up to $8 billion for a company whose biggest product is losing steam? Because Lantheus isn't standing still. The company recently won FDA approval for PYLARIFY TruVu, a reformulated version designed to improve manufacturing efficiency and margins. A phased commercial launch starts in Q4 2026. Beyond that, two new diagnostic agents are approaching FDA decisions: OCTEVY for neuroendocrine tumor imaging (PDUFA date: June 2026) and MK-6240, a tau-targeted Alzheimer's PET tracer (PDUFA date: August 2026).
The CVR structure of the deal actually reflects this dynamic. The upfront $102.50 per share prices in PYLARIFY's current trajectory. The extra $12.00 per share in CVRs rewards shareholders if the pipeline delivers. Risk transferred; upside preserved.
Wall Street's Verdict: Fair Price, Don't Expect a Bidding War
Analysts aren't exactly popping champagne, but they're nodding approvingly. William Blair downgraded Lantheus from Outperform to Market Perform after the announcement, calling the merger an "excellent outcome" for shareholders but noting that most of the upside is now baked into the deal price.
Blair's rationale is straightforward: the $102.50 cash component sits right near their intrinsic value estimate of roughly $101 per share, and the maximum $114.50 (with CVRs) lines up with the bullish targets that Mizuho and Citizens had set at $120 and $115, respectively. In other words, Curium is paying close to full value.
Perhaps more importantly, Blair explicitly stated it does not expect a competing bid. The reasoning is practical: radiopharmaceuticals require specialized isotope production, complex just-in-time logistics for products with short half-lives, and strict regulatory expertise. The number of companies that can actually integrate a platform like Lantheus is vanishingly small.
The Bigger Picture: Nuclear Medicine's Gold Rush
Zoom out, and the Curium-Lantheus deal is just the latest (and largest) domino in a radiopharmaceutical M&A frenzy that's been building for years.
In 2024 alone, the sector saw a surge in major deals. Bristol Myers Squibb bought RayzeBio for $4.1 billion. AstraZeneca grabbed Fusion Pharmaceuticals for up to $2.4 billion. Eli Lilly acquired Point Biopharma for $1.4 billion. Novartis paid $1 billion for Mariana Oncology. That's four major platform acquisitions in a single year, all focused on targeted radiotherapy for cancer.
The money keeps flowing because the market is exploding. Depending on which research firm you ask, the global radiopharmaceutical market sits at roughly $7.5 billion today and is projected to grow rapidly through the early 2030s. That's a market poised for dramatic expansion in under a decade.
What's driving it? Two words: theranostics and oncology. The ability to use one radioactive agent to find a tumor and a matched agent to treat it is transforming cancer care. Novartis' Lutathera and Pluvicto (for neuroendocrine tumors and prostate cancer, respectively) are already combined blockbusters, expected to exceed $2 billion in annual sales. Every major pharma company now wants its own version of that playbook.
What Happens Next
The Curium-Lantheus merger still needs shareholder votes and regulatory sign-offs before it can close. But barring surprises, the combined company will emerge as arguably the world's most complete radiopharmaceutical platform: isotope production, diagnostic imaging, targeted therapy, and a global distribution network, all under one roof.
For the broader sector, the message is clear. Radiopharmaceuticals have gone from a niche corner of nuclear medicine to one of the hottest strategic battlegrounds in all of biopharma. Companies like Novartis, Eli Lilly, AstraZeneca, and BMS have already planted their flags. Curium just planted the biggest one yet.
The nuclear medicine arms race isn't slowing down. If anything, $8 billion says it's just getting started.
5 min read
Two CNS Pharma Companies Just Stitched Themselves Together. Here's Why.
Supernus and Indivior are merging into a $2.2 billion CNS and addiction powerhouse, combining ADHD drugs with the dominant opioid treatment franchise. It's specialty pharma's latest bet that brain disorders and addiction belong under one roof.
